111 related articles for article (PubMed ID: 38301967)
1. Cediranib enhances the transcription of MHC-I by upregulating IRF-1.
Zhang J; Guo H; Wang L; Zheng M; Kong S; Wu H; Zhao L; Zhao Q; Yang X; He Q; Chen X; Ding L; Yang B
Biochem Pharmacol; 2024 Mar; 221():116036. PubMed ID: 38301967
[TBL] [Abstract][Full Text] [Related]
2. Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cells.
Tu J; Xu H; Ma L; Li C; Qin W; Chen X; Yi M; Sun L; Liu B; Yuan X
Theranostics; 2022; 12(2):747-766. PubMed ID: 34976211
[No Abstract] [Full Text] [Related]
3. Cancer cell-intrinsic expression of MHC II in lung cancer cell lines is actively restricted by MEK/ERK signaling and epigenetic mechanisms.
Neuwelt AJ; Kimball AK; Johnson AM; Arnold BW; Bullock BL; Kaspar RE; Kleczko EK; Kwak JW; Wu MH; Heasley LE; Doebele RC; Li HY; Nemenoff RA; Clambey ET
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32312906
[TBL] [Abstract][Full Text] [Related]
4. Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis.
Takahashi O; Komaki R; Smith PD; Jürgensmeier JM; Ryan A; Bekele BN; Wistuba II; Jacoby JJ; Korshunova MV; Biernacka A; Erez B; Hosho K; Herbst RS; O'Reilly MS
Clin Cancer Res; 2012 Mar; 18(6):1641-54. PubMed ID: 22275507
[TBL] [Abstract][Full Text] [Related]
5. Two distinct gamma interferon-inducible promoters of the major histocompatibility complex class II transactivator gene are differentially regulated by STAT1, interferon regulatory factor 1, and transforming growth factor beta.
Piskurich JF; Linhoff MW; Wang Y; Ting JP
Mol Cell Biol; 1999 Jan; 19(1):431-40. PubMed ID: 9858567
[TBL] [Abstract][Full Text] [Related]
6. Interferon regulatory factor 1 priming of tumour-derived exosomes enhances the antitumour immune response.
Yang MQ; Du Q; Varley PR; Goswami J; Liang Z; Wang R; Li H; Stolz DB; Geller DA
Br J Cancer; 2018 Jan; 118(1):62-71. PubMed ID: 29112686
[TBL] [Abstract][Full Text] [Related]
7. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
8. IL-9 stimulates an anti-tumor immune response and facilitates immune checkpoint blockade in the CMT167 mouse model.
Feng Y; Yan S; Lam SK; Ko FCF; Chen C; Khan M; Ho JC
Lung Cancer; 2022 Dec; 174():14-26. PubMed ID: 36272280
[TBL] [Abstract][Full Text] [Related]
9. Butein suppresses PD-L1 expression via downregulating STAT1 in non-small cell lung cancer.
Zhao L; Zhang W; Luan F; Chen X; Wu H; He Q; Weng Q; Ding L; Yang B
Biomed Pharmacother; 2023 Jan; 157():114030. PubMed ID: 36455456
[TBL] [Abstract][Full Text] [Related]
10. Synergistic stimulation of MHC class I and IRF-1 gene expression by IFN-gamma and TNF-alpha in oligodendrocytes.
Agresti C; Bernardo A; Del Russo N; Marziali G; Battistini A; Aloisi F; Levi G; Coccia EM
Eur J Neurosci; 1998 Sep; 10(9):2975-83. PubMed ID: 9758167
[TBL] [Abstract][Full Text] [Related]
11. N
Liu Z; Wang T; She Y; Wu K; Gu S; Li L; Dong C; Chen C; Zhou Y
Mol Cancer; 2021 Aug; 20(1):105. PubMed ID: 34416901
[TBL] [Abstract][Full Text] [Related]
12. Acute vascular response to cediranib treatment in human non-small-cell lung cancer xenografts with different tumour stromal architecture.
Jiang Y; Allen D; Kersemans V; Devery AM; Bokobza SM; Smart S; Ryan AJ
Lung Cancer; 2015 Nov; 90(2):191-8. PubMed ID: 26323213
[TBL] [Abstract][Full Text] [Related]
13. IFN regulatory factor-1 gene transfer into an aggressive, nonimmunogenic sarcoma suppresses the malignant phenotype and enhances immunogenicity in syngeneic mice.
Yim JH; Wu SJ; Casey MJ; Norton JA; Doherty GM
J Immunol; 1997 Feb; 158(3):1284-92. PubMed ID: 9013971
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of galectin-3 augments the antitumor efficacy of PD-L1 blockade in non-small-cell lung cancer.
Zhang H; Liu P; Zhang Y; Han L; Hu Z; Cai Z; Cai J
FEBS Open Bio; 2021 Mar; 11(3):911-920. PubMed ID: 33455075
[TBL] [Abstract][Full Text] [Related]
15. Mutational activation of the epidermal growth factor receptor down-regulates major histocompatibility complex class I expression via the extracellular signal-regulated kinase in non-small cell lung cancer.
Watanabe S; Hayashi H; Haratani K; Shimizu S; Tanizaki J; Sakai K; Kawakami H; Yonesaka K; Tsurutani J; Togashi Y; Nishio K; Ito A; Nakagawa K
Cancer Sci; 2019 Jan; 110(1):52-60. PubMed ID: 30390416
[TBL] [Abstract][Full Text] [Related]
16. Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study.
Goss GD; Arnold A; Shepherd FA; Dediu M; Ciuleanu TE; Fenton D; Zukin M; Walde D; Laberge F; Vincent MD; Ellis PM; Laurie SA; Ding K; Frymire E; Gauthier I; Leighl NB; Ho C; Noble J; Lee CW; Seymour L
J Clin Oncol; 2010 Jan; 28(1):49-55. PubMed ID: 19917841
[TBL] [Abstract][Full Text] [Related]
17.
Velásquez LN; Milillo MA; Delpino MV; Trotta A; Fernández P; Pozner RG; Lang R; Balboa L; Giambartolomei GH; Barrionuevo P
J Leukoc Biol; 2017 Mar; 101(3):759-773. PubMed ID: 27765819
[No Abstract] [Full Text] [Related]
18. Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action.
Xue Y; Gao S; Gou J; Yin T; He H; Wang Y; Zhang Y; Tang X; Wu R
Expert Opin Drug Deliv; 2021 Feb; 18(2):187-203. PubMed ID: 32954856
[TBL] [Abstract][Full Text] [Related]
19. Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing.
Leclerc M; Mezquita L; Guillebot De Nerville G; Tihy I; Malenica I; Chouaib S; Mami-Chouaib F
Front Immunol; 2019; 10():1505. PubMed ID: 31333652
[TBL] [Abstract][Full Text] [Related]
20. IFN-gamma-induced MHC class II expression: transactivation of class II transactivator promoter IV by IFN regulatory factor-1 is regulated by protein kinase C-alpha.
Giroux M; Schmidt M; Descoteaux A
J Immunol; 2003 Oct; 171(8):4187-94. PubMed ID: 14530341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]